MX2021003643A - Derivados de terpenoides y usos de los mismos. - Google Patents

Derivados de terpenoides y usos de los mismos.

Info

Publication number
MX2021003643A
MX2021003643A MX2021003643A MX2021003643A MX2021003643A MX 2021003643 A MX2021003643 A MX 2021003643A MX 2021003643 A MX2021003643 A MX 2021003643A MX 2021003643 A MX2021003643 A MX 2021003643A MX 2021003643 A MX2021003643 A MX 2021003643A
Authority
MX
Mexico
Prior art keywords
terpinoid
derivatives
compounds
compositions
useful
Prior art date
Application number
MX2021003643A
Other languages
English (en)
Inventor
Gene Hung
Stephen W Kaldor
Bohan Jin
Qing Dong
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of MX2021003643A publication Critical patent/MX2021003643A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente derivados terpenoides como inhibidores de NRF2 y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones objetivo son útiles para el tratamiento de enfermedades inflamatorias.
MX2021003643A 2018-09-28 2019-09-23 Derivados de terpenoides y usos de los mismos. MX2021003643A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862738762P 2018-09-28 2018-09-28
US201862770569P 2018-11-21 2018-11-21
US201962808192P 2019-02-20 2019-02-20
US201962823846P 2019-03-26 2019-03-26
PCT/US2019/052472 WO2020068689A1 (en) 2018-09-28 2019-09-23 Terpinoid derivatives and uses thereof

Publications (1)

Publication Number Publication Date
MX2021003643A true MX2021003643A (es) 2021-08-19

Family

ID=69953539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003643A MX2021003643A (es) 2018-09-28 2019-09-23 Derivados de terpenoides y usos de los mismos.

Country Status (9)

Country Link
US (1) US20220017566A1 (es)
EP (1) EP3856755A4 (es)
JP (1) JP2022501445A (es)
CN (1) CN113366010A (es)
AU (1) AU2019346395A1 (es)
BR (1) BR112021005919A2 (es)
CA (1) CA3114354A1 (es)
MX (1) MX2021003643A (es)
WO (1) WO2020068689A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115087660A (zh) * 2019-12-19 2022-09-20 里亚塔医药公司 在c-17处具有基于氮的取代基的合成三萜类化合物及其使用方法
WO2022126129A1 (en) * 2020-12-11 2022-06-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids for use in therapy
JP2024504637A (ja) * 2021-01-18 2024-02-01 リアタ ファーマシューティカルズ インコーポレイテッド 合成ウルソール酸誘導体及びその使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201004627A (en) * 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
LT2276493T (lt) * 2008-04-18 2019-01-10 Reata Pharmaceuticals, Inc. Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17
CA2829618C (en) * 2011-03-11 2019-07-09 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
EP2892910B1 (en) * 2012-09-10 2016-09-07 AbbVie Inc. Glycyrrhetinic acid derivatives with anti-inflammatory activity
HUE036797T2 (hu) * 2012-09-10 2018-07-30 Reata Pharmaceuticals Inc Oleanolsav C17-heteroaril-származékai és azok alkalmazási eljárásai
NZ756256A (en) * 2013-08-23 2021-07-30 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
JP2022501445A (ja) 2022-01-06
US20220017566A1 (en) 2022-01-20
AU2019346395A1 (en) 2021-04-22
EP3856755A4 (en) 2022-12-28
CA3114354A1 (en) 2020-04-02
CN113366010A (zh) 2021-09-07
BR112021005919A2 (pt) 2021-07-27
EP3856755A1 (en) 2021-08-04
WO2020068689A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2023002507A (es) Inhibidores de cd73.
EP3866781A4 (en) NEW COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3693369A3 (en) Bromodomain inhibitors
ZA201904522B (en) Heterocyclic inhibitors of mct4
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
MX2022005256A (es) Inhibidores de cd73.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
EP3685840A4 (en) PHARMACEUTICAL COMPOSITION OF COMPOUNDS FOR TREATING INFLAMMATORY SKIN DISEASES
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
MX2019004375A (es) Inhibidores de bromodominios.
WO2018211324A8 (en) Prodrugs for the treatment of disease
ZA202005083B (en) Solid forms of fasoracetam
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
MX2019004187A (es) Inhibidores de bromodominios.
EP3804736A4 (en) PHARMACEUTICAL COMPOSITION WITH MESENCHYMAL STEM CELLS AS AN EFFECTIVE INGREDIENT TO PREVENT OR TREAT AN INFLAMMATORY DISEASE